aslan pharmaceuticals pte ltd
10 Of Singapore’s Hottest Biotech Startups
Check out these ten biomedical startups leading healthcare innovation from the little red dot.
ASLAN, A*STAR To Develop Therapeutic Antibody Against RON Kinase
ASLAN Pharmaceuticals will license a therapeutic antibody from A*STAR that targets the macrophage-stimulating protein receptor, also known as Recepteur d’Origine Nantais kinase.
Bristol-Myers Squibb Reacquires Rights To ASLAN Drug
Bristol-Myers Squibb will be reacquiring the rights to ASLAN002, a gastric and breast cancer drug, for several APAC markets.
ASLAN Pharma Raises US$23 Million In Pre-IPO Financing Round
The financing round has attracted support from both new and existing investors, including from Taiwan.
ASLAN’s Varlitinib Receives Orphan Drug Designation For Gastric Cancer
Varlitinib previously received orphan drug designation for cholangiocarcinoma in August 2015.
ASLAN Closes Series C Financing Round Of US$43 Million
The additional investment of US$9 million will enable ASLAN to develop its licensing agreement for the rheumatoid arthritis drug LAS186323.
ASLAN Raises US$34 Million For Immuno-Oncology
The US$34 million in Series C funding will be used to complete at least ten clinical studies for ASLAN's lead compound, ASLAN001.
ASLAN & Hyundai Pharm Collaborate To Develop Cancer Drug
The two companies will conduct clinical trials to assess varlitinib in the treatment of aggressive bile duct cancer, a disease prevalent in South Korea.
ASLAN’s Bile Duct Cancer Drug Given FDA Orphan Drug Status
ASLAN001 has been awarded orphan drug designation to treat cholangiocarcinoma, a rare and aggressive form of bile duct cancer.
ASLAN Commences Taiwan Trials For Gastric Cancer Drug
ASLAN has begun treating its first gastric cancer patients in Taiwan, where 4,000 people are affected by the disease annually.
